Supplements
bromelain decreases post-surgical swelling and pain
In plain terms: Does bromelain reduce swelling after surgery?
Strong support Supplements
Part of: 🧪 bromelain
RefutedContestedStrong support
consensus score 0.86
Yes — this is its best-proven use. Trials (mostly after dental surgery) show oral bromelain cuts post-op swelling, pain and jaw-stiffness, in one study as well as the drug diclofenac. Small and mostly dental, but real.
📅 Last reviewed: 2026-07-15 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: All trials, pooled (Meta-analysis)
MechanismIn-vitroAnimalObservationalRCTMeta-analysis
How the studies fall
3 support 0 contradict 0 tested null 1 mixed · 4 sources, 3 independent groups
What the evidence shows
Bromelain's best-evidenced oral use. Randomized trials — mostly after dental (third-molar) surgery — find oral bromelain reduces post-operative swelling, pain and jaw-stiffness, in one trial comparably to the anti-inflammatory drug diclofenac. Solid in the surgical setting, though the trials are small and mostly dental.
The evidence (6)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Ho 2016 · Dermatol Surg | observational | mixed | low | Systematic review of 20 post-procedure trials (7 oral bromelain): 'Some randomized controlled trials reported improvement postprocedure with arnica (4/13) and bromelain (5/7)', but the authors conclude 'there is insufficient data to support use of arnica and bromelain post procedure'. Secondary source - non-voting. |
| Gupta AA et al 2022 · J Dent Anesth Pain Med | RCT | supports | moderate | Triple-blind randomized trial, n=72 (36/36), single centre in Wardha India, no placebo arm: oral bromelain 500 mg 8-hourly x5 d (Simply Nutra) vs aceclofenac 100 mg 12-hourly after removal of an impacted mandibular third molar. Swelling was lower on bromelain at both follow-ups (18.28 +/- 0.73 and 14.74 +/- 1.03 on days 2 and 7 vs 24.12 +/- 1.54 and 15.46 +/- 1.14 on aceclofenac): 'Group B demonstrated a significant decrease in the severity of edema and trismus compared to group A on both PO days 2 and 7 (P < 0.001).' Trismus followed the same direction (mouth opening 24.30 vs 21.44 mm at day 2). PAIN, the other half of this claim, was NOT reduced relative to the comparator: 'Bromelain demonstrated similar analgesic efficacy with an insignificant difference compared to aceclofenac (P > 0.05)' (VAS P = 0.47 and 0.32; rescue analgesics P = 0.25). Adverse effects 9% on bromelain vs 60% on aceclofenac (Discussion says 70% for the same group — the paper is internally inconsistent here, and its day-2/day-7 VAS values are swapped between the Results prose and Table 2). Active-comparator superiority on swelling only; unregistered, single surgeon, no placebo, so this cannot show benefit versus no treatment. |
| Majid OW, Al-Mashhadani BA 2014 · J Oral Maxillofac Surg | RCT | mixed | low | Three-arm double-blind RCT, 45 patients (15/arm), single partial bony impacted mandibular third molar; oral bromelain 4 x 250 mg/d vs diclofenac sodium 4 x 25 mg/d vs placebo, started 1 day pre-op for 4 days; outcomes at days 1, 3, 7. Pain — positive: 'The bromelain and diclofenac groups both showed a significant reduction in pain compared with the placebo group at all intervals (P < .05).' Swelling — NULL for bromelain: 'Diclofenac also resulted in a significant reduction of swelling at 3 and 7 days, and bromelain resulted in an insignificant reduction.' Trismus — null in both arms: 'A nonsignificant reduction in trismus occurred in both treatment groups compared with the placebo group.' QOL — positive: 'Both treatment groups also showed a significant difference in the effect on QOL in most subscales and total scores (P < .05).' The trial's 'comparable' finding is between the two active drugs, not versus placebo: 'The effect was comparable between the 2 treatment groups for all parameters and at all intervals.' Mixed on this compound claim: bromelain beat placebo on pain but not on swelling, the half the claim is named for. At 15/arm the swelling and trismus nulls are underpowered, so they are not evidence of no effect either. Note that the article title ('reduces pain and swelling') overstates its own Results. Read from the PubMed abstract only; no PMC record, full text not obtainable. |
| Consorti G et al 2024 · J Clin Med | RCT | supports | low | Prospective, randomized, OPEN-LABEL, no-placebo trial, n=100 (50/50), maxillofacial fracture surgery, Ancona Italy. Group B took Brovas(R) twice daily for 15 days - a COMBINATION of bromelain 700 mg/day (2400 GDU/g) PLUS Aesculus hippocastanum 370 mg/day and Melilotus officinalis 200 mg/day, both coumarin-titrated anti-edema botanicals; Group A took nothing. Edema by facial-landmark distances: 'difference was significantly lower in group B than in control for all landmarks' - but reported with no per-group values, no effect sizes and no p-values, across nine landmarks with no multiplicity adjustment, and only AFTER the pre-stated over-time test failed ('the real underlying hypothesis should be that at T2 swelling increases less in groups using the treatment than in control groups'). Analgesia: 'The median of group A is equal to 4 days of anti-inflammatory treatment while the median of group B is equal to 2 days' (p<0.0001). Mouth opening 4.2 vs 4.7 cm at day 7, converging to 4.9 vs 5.1 cm at day 15, no p-values. Held at quality low: no bromelain-only arm so the effect cannot be attributed to bromelain, 'it was not possible to conduct it in a double-blind manner' with an untreated rather than placebo control, power computed post hoc, no registration and no ethics-committee review. The printed VAS pain result is internally contradictory - 'significantly lower values for group B with a value of 3.26 +/- 1.26 versus the value of 2.24 +/- 1.15 for group A' has the treated arm numerically higher, so the group labels appear transposed. |
| Orsini, Plastic Surgery Educational Foundation Technology Assessment Committee 2006 · Plast Reconstr Surg | observational | supports | low | Narrative review, no primary data: bromelain may be of interest to plastic surgeons because of its apparent ability to reduce pain, edema, inflammation and platelet aggregation, which may be beneficial in postoperative healing; the same abstract concludes that more randomized, controlled clinical trials are necessary to further elucidate its clinical potential. |
| Liu, Zhao, Wang, Zhao, Ma 2019 · J Oral Maxillofac Surg | meta-analysis | supports | moderate | Meta-analysis of 6 RCTs (impacted mandibular third-molar surgery, oral bromelain vs placebo): swelling reduced at both timepoints (early SMD -0.24, 95% CI -0.46 to -0.02, P = .03; late SMD -0.54, 95% CI -0.84 to -0.24, P = .0004); pain reduced at 7 days (SMD -0.54, 95% CI -0.87 to -0.20, P = .002) but not at 2-3 days; trismus unaffected at either timepoint. Authors' own summary: 'Bromelain conferred moderate relief of postoperative discomfort'. |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.